國家衛生研究院 NHRI:Item 3990099045/6050

NHRI > Institute of Biotechnology and Pharmaceutical Research > Yueh Andrew Yueh > Periodical Articles > Item 3990099045/6050

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/6050

Title:	Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor
Authors:	Lin, HM;Wang, JC;Hu, HS;Wu, PS;Yang, CC;Wu, CP;Pu, SY;Hsu, TA;Jiaang, WT;Chao, YS;Chern, JH;Yeh, TK;Yueh, A
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	Hepatitis C virus (HCV) is a global health problem, affecting approximately 3% of the world's population. The standard treatment for HCV infection is often poorly tolerated and ineffective. Therefore, the development of novel or more effective treatment strategies to treat chronic HCV infection is urgently needed. In this report, BP008, a potent small-molecule inhibitor of HCV replication was developed from a class of compounds with thiazol core structure by means of utilizing a cell-based HCV replicon system. The compound reduced the reporter expression of the HCV1b replicon with an EC(50) and selective index value of 4.1 +/- 0.7 nM and >12,195, respectively. Sequencing analyses of several individual clones derived from BP008-resistant RNAs purified from cells harboring HCV1b replicon revealed that amino acid substitutions mainly within the N-terminal region (domain I) of NS5A were associated with decreased inhibitor susceptibility. Q24L, P58S and Y93H are the key substitutions for resistance selection; F149L and V153M play the compensatory role in the replication and drug resistance processes. Moreover, BP008 displayed synergistic effects with interferon alpha (IFN-alpha), NS3 protease inhibitor, and NS5B polymerase inhibitor, as well as good oral bioavailability in SD rats and favorable exposure in rat liver. In summary, our results presented an effective small-molecule inhibitor, BP008, potentially targeting at HCV NS5A. BP008 can be considered as part of a more effective therapeutic strategy for HCV in the future.
Date:	2012-01
Relation:	Antimicrobial Agents and Chemotherapy. 2012 Jan;56(1):44-53.
Link to:	http://dx.doi.org/10.1128/aac.00599-11
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000298404900006
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84455161734
Appears in Collections:	[Yueh Andrew Yueh] Periodical Articles [Teng-Kuang Yeh] Periodical Articles [Jyh-Haur Chern] Periodical Articles [Yu-Sheng Chao(2002-2013)] Periodical Articles [Weir-Torn Jiaang] Periodical Articles [John Tsu-An Hsu] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB22006008.pdf		448Kb	Adobe PDF	793	View/Open

Loading...